Introduction
============

Transcatheter aortic valve replacement (TAVR) enables the safe and effective treatment of inoperable or high-surgical-risk patients with severe aortic valve disease, without using a cardiopulmonary bypass ([@ref-27]; [@ref-31]). Randomized controlled trials have demonstrated that TAVR is an effective alternative to surgical aortic valve replacement in intermediate-risk patients ([@ref-30]; [@ref-37]).

Transcatheter aortic valve replacement is more favorable than surgical aortic valve replacement when using transfemoral (TF) access ([@ref-16]), which is thus used as the default approach for performing TAVR in numerous institutions. However, peripheral vascular occlusion, stenosis, calcification, or tortuosity precludes TF access in approximately 10% of patients ([@ref-19]), necessitating the use of an alternative route, such as transapical (TA), transaxillary (TAx), direct aortic (DAo), and transcarotid routes. To select the optimal treatment technique in patients unsuitable for TF TAVR, clinicians need to understand the outcomes of using different nonfemoral routes.

Transapical route was the first alternative TAVR route developed for patients with unsuitable iliofemoral vessels ([@ref-19]; [@ref-47]). However, the procedure is associated with relatively high rates of bleeding, ventricular damage ([@ref-2]), myocardial injury ([@ref-38]), and mortality ([@ref-15]; [@ref-34]). DAo and TAx routes are also principal alternatives to TF; both have results comparable to those of the TF route ([@ref-1]; [@ref-3]; [@ref-8]; [@ref-15]). However, data comparing the outcomes of using the DAo and TAx TAVR routes are limited. Therefore, we conducted this systematic review and meta-analysis to compare the morbidity and mortality associated with these two approaches.

Materials and Methods
=====================

Literature search
-----------------

This systematic review of published studies was performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, with a PRISMA checklist provided as [Table S1](#supp-4){ref-type="supplementary-material"}. This study has been prospectively registered with PROSPERO (registration number: CRD42017069788). A computerized search of the Medline, PubMed, Embase, and Cochrane databases was performed to identify all relevant studies published before December 31, 2019 by using the following keywords: "transcatheter," "aortic valve," "TAVR," "TAVI," "direct aortic," "transaortic," "transaxillary," "axillary," "trans-subclavian," and "subclavian." The exact string of keywords is reported in [Supplemental Material 1](#supp-1){ref-type="supplementary-material"}. Review articles or meta-analyses were not included for analysis, but their citations and references were searched for additional relevant studies. Citations were screened at the title and abstract levels and retrieved as a full report if outcome data of TAVRs were provided. Two evaluators (H.A. Lee and S.W. Chen) independently searched for and reviewed the articles. Discrepancies were discussed and resolved through consensus.

Study selection
---------------

Inclusion criteria were as follows: (1) original article in English with full-length content available, (2) at least 10 consecutive patients who underwent either DAo or TAx TAVR, (3) outcomes defined using the Valve Academic Research Consortium (VARC) definition (as VARC-1 or VARC-2) ([@ref-24]; [@ref-29]), and (4) separate results for patients undergoing DAo TAVR or TAx TAVR. Exclusion criteria were as follows: (1) overlapping patients or subgroup studies of the main study, (2) studies that focused on the valve-in-valve procedure, (3) studies that focused on TAVR combined with another procedure, and (4) the use of devices other than Medtronic CoreValve (MCV; Medtronic, Minneapolis, MN, USA) and Edwards Valve (EV; Edwards Lifesciences, Irvine, CA, USA). Studies that did not directly compare the 2 approaches were also included. The most recent publications were retained when two or more similar studies were reported by the same institution or author.

Data extraction
---------------

Relevant information was collected by H.A. Lee and S.W. Chen. The study-level characteristics extracted were first author name, publication year, study type (e.g., single-centered or multicentered), number of studies, location, study period, route (DAo or TAx), patient number, and VARC version ([Table 1](#table-1){ref-type="table"}). The arm-level characteristics items extracted included age, logistic EuroSCORE, Society of Thoracic Surgery (STS) score, comorbidities, previous cardiac surgery, left ventricular ejection fraction, and devices ([Table 2](#table-2){ref-type="table"}). Data on the primary and secondary outcomes for either DAo or TAx were also collected.
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###### Study data.
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  First author   Year   Locations/country   Study type      No. of centers   Study period   Access     Patient number   VARC
  -------------- ------ ------------------- --------------- ---------------- -------------- ---------- ---------------- ------
  Khan           2018   US                  Single center   1                2013--2015     TAx, DAo   51               2
  Damluji        2018   US, France          Multi-center    3                2008--2017     TAx, DAo   84               2
  Fiorina        2016   Italy               Multi-center    4                2007--2014     TAx, DAo   147              2
  Adamo          2015   Italy               Single center   1                2007--2014     TAx, DAo   32               2
  Zhan           2020   US                  Single center   1                2015--2018     TAx        10               2
  Dahle          2019   US                  Multi-center    NA               2015--2018     TAx        1249             2
  Hysi           2019   France              Single center   1                2015--2017     TAx        43               2
  Gleason        2018   US                  Multi-center    45               NA             TAx        202              1
  Terzian        2017   France              Single center   1                2006--2014     TAx        36               1
  Schäfer        2017   Germany             Multi-center    2                2010--2016     TAx        100              2
  Laflamme       2014   Canada              Single center   1                2010--2012     TAx        18               2
  Muensterer     2013   Germany             Single center   1                2007--2011     TAx        40               2
  Testa          2012   Italy               Single center   1                NA             TAx        70               1
  Gilard         2012   France              Multi-center    34               2010--2011     TAx        184              1
  Romano         2019   France              Single center   1                2011--2014     DAo        265              2
  Cocchieria     2019   Eurpoe              Multi-center    18               2013--2015     DAo        253              2
  D'Ancona       2019   German              Single center   1                2012--2014     DAo        106              2
  Petzina        2017   Germany             Single center   1                2012--2014     DAo        99               2
  Bruschi        2017   Europe              Multi-center    9                2012--2014     DAo        92               2
  Bonaros        2017   Europe              Multi-center    18               2013--2015     DAo        301              2
  Ropponen       2016   Finland             Single center   1                2008--2014     DAo        36               1
  Arai           2016   France              Single center   1                2011--2014     DAo        289              2
  Wendt          2015   Germany             Single center   1                2012--2014     DAo        30               1
  Thourani       2015   US                  Multi-center    NA               2011--2014     DAo        868              2
  Ribeiro        2015   Canada              Single center   1                2007--2015     DAo        45               2
  Ramlawi        2015   US                  Single center   1                2011--2015     DAo        78               2
  Okuyama        2015   US                  Single center   1                2007--2014     DAo        51               2
  Jagielak       2015   Poland              Multi-center    NA               2013--2014     DAo        32               2
  Bruschi        2015   Italy               Single center   1                2008--2013     DAo        50               2
  Spargias       2014   Greece              Single center   1                NA             DAo        25               1
  Dahle          2014   Norway              Single center   1                2009--2013     DAo        30               1

**Note:**

Basic information of studies included in the meta-analysis. DAo, direct aortic; NA, not available; VARC, Valve Academic Research Consortium; TAx, transaxillary; US, the United States.
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###### Baseline and procedural characteristics of patients.
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  Variable                                DAo patients   TAx patients           
  --------------------------------------- -------------- -------------- ------- ------------
  Age, year                               2,236          82.7 ± 1.2     2,136   80.0 ± 1.7
  Logistic EuroSCORE                      642            22.0 ± 7.1     681     22.6 ± 5.3
  STS score                               1,161          7.5 ± 1.8      1,737   8.9 ± 3.0
  Old Stroke, %                           1,957          12.1           1,957   12.1
  Atrial fibrillation, %                  1,152          28.6           590     39.0
  Peripheral arterial disease, %          2,035          41.6           1,919   64.4
  Chronic kidney disease, %               1,946          28.5           557     16.0
  Previous cardiac surgery, %             1,961          23.6           870     23.5
  Left ventricular ejection fraction, %   1,965          62.3 ± 9.7     311     52.1 ± 1.6
  Device (CoreValve, %)                   2,847          23.2           1,852   29.3

**Note:**

DAo, direct aortic; TAx, transaxillary; SD, standard deviation.

Outcome measures
----------------

The primary outcomes were 30-day stroke and mortality rates after TAx or DAo TAVR. These results were further stratified by mean STS scores of \<8 and ≥8 after TAx or DAo TAVR. The 30-day stroke rates after MCV and EV use were also compared. If a study did not report the 30-day mortality or stroke rates, in-hospital mortality or stroke rates were used. The secondary outcomes were device success, conversion to traditional surgery, valve malposition, acute kidney injury, major bleeding, major vascular complication, new permanent pacemaker (PPM) implantation, paravalvular leakage (PVL) grade of ≥2, 30-day cardiovascular mortality, and 1-year mortality.

Quality assessment
------------------

We assessed the quality of the included studies by using the Newcastle-Ottawa Scale (NOS) ([@ref-48]). Quality scores ranged from 0 (lowest) to 8 (highest). The NOS was applied to each article separately by H.A. Lee and S.W. Chen and disagreements were resolved by consensus between the 2 reviewers.

Statistical analysis
--------------------

This meta-analysis included studies that did not directly compare the two approaches and pooled rates of events from the included studies for comparison. Random-effects models were used to pool the estimates of primary and secondary outcomes from individual studies for each arm (TAx or DAo). In contrast to a fixed-effects model, a random-effects model enables the true underlying effect to vary among individual studies. *I*^2^ above 25%, 50%, and 75% were considered to represent low, moderate, and high heterogeneity across the studies, respectively ([@ref-20]). The pooled estimates between TAx and DAo TAVR were compared using mixed-effects models. Statistical significance was set at *P* \< 0.05 with a two-tailed test. Data were analyzed using Comprehensive Meta-Analysis (version 2.2; Biostat, Englewood, NJ, USA).

Results
=======

Literature search
-----------------

Our initial web-based literature search yielded 703 records. We screened the titles and abstracts of all 703 studies, of which 583 did not satisfy our inclusion and exclusion criteria. We downloaded and assessed the full-text of 120 articles for eligibility. After a review of the full-text articles, we excluded 19 articles that employed duplicated cohorts, 49 that did not report the outcomes of patients who received TAx or DAo TAVR, 13 that did not use VARC definitions for reporting the outcomes, one that included only TAVR with combined coronary artery bypass grafting procedure, four that used devices other than Edward or Medtronic, one that enrolled \<10 cases, and one that employed a valve-in-valve procedure ([Supplemental Material 2](#supp-2){ref-type="supplementary-material"}, [Table S2](#supp-5){ref-type="supplementary-material"}). Thus these 31 studies were used in the quantitative meta-analysis ([Fig. 1](#fig-1){ref-type="fig"}), with 2,883 and 2,172 patients in the DAo TAVR and TAx TAVR groups, respectively ([@ref-1]; [@ref-3]; [@ref-5]; [@ref-6], [@ref-7]; [@ref-9]; [@ref-10]; [@ref-11]; [@ref-12]; [@ref-13]; [@ref-14]; [@ref-17]; [@ref-18]; [@ref-21]; [@ref-22]; [@ref-25]; [@ref-28]; [@ref-32]; [@ref-33]; [@ref-35]; [@ref-36]; [@ref-38]; [@ref-39]; [@ref-40]; [@ref-41]; [@ref-42]; [@ref-43]; [@ref-44]; [@ref-45]; [@ref-49]; [@ref-50]).

![Flow of study selection process.\
CABG, coronary arterial bypass grafting; DAo, direct aortic approach; TAx, transaxillary; VARC, Valve Academic Research Consortium.](peerj-08-9102-g001){#fig-1}

Quality assessment
------------------

The quality of the 31 studies included in the meta-analysis was assessed using NOS, scored in the range of 0--8 points. The NOS scores for all 31 studies ranged between 5 and 7 points, with a median score of 6 points ([Table S3](#supp-6){ref-type="supplementary-material"}).

Baseline and procedural characteristics
---------------------------------------

[Table 2](#table-2){ref-type="table"} presents the available baseline and procedural characteristics. The mean age of the DAo TAVR and TAx TAVR groups was 82.7 ± 1.2 and 80.0 ± 1.7 years, respectively. No substantial differences in logistic EuroSCORE (22.0 ± 7.1 in DAo vs. 22.6 ± 5.3 in TAx) and STS score (7.5 ± 1.8 in DAo vs. 8.9 ± 3.0 in TAx) were noted. The percentage of MCV use in the TAx TAVR group seemed to be higher than that in the DAo TAVR group.

TAx and DAo TAVR outcomes
-------------------------

We analyzed the two primary outcomes, the 30-day stroke and mortality rates ([Fig. 2](#fig-2){ref-type="fig"}). The 30-day mortality rates of the DAo TAVR and TAx TAVR groups were significantly different with mortality rates of 9.6% (95% confidence interval (CI) \[8.4--10.9\]) and 5.7% (95% CI \[4.8--6.8\]), respectively (*P* for heterogeneity \< 0.001). The pooled 30-day stroke rate in the DAo TAVR group (2.6%, 95% CI \[1.9--3.4\]) was significantly lower than that in the TAx TAVR group (5.8%, 95% CI \[4.9--7.0\]; *P* for heterogeneity \< 0.001).

![Forrest plot of TAx and DAo TAVR outcomes.\
The pooled incidence of mortality, stroke, and other complications of TAx and DAo TAVR. DAo, direct aortic; TAVR, transcatheter aortic valve replacement; TAx, transaxillary.](peerj-08-9102-g002){#fig-2}

We then analyzed secondary outcomes. Patients were more likely to require new PPM implantation after TAx TAVR (20.1%, 95% CI \[15.5--25.6\]) than after DAo TAVR (12.3%, 95% CI \[9.4--16.0\]; *P* for heterogeneity = 0.009). Valve malposition occurred more frequently in patients who underwent TAx TAVR (10.2%, 95% CI \[3.4--27.1\]) than in patients who underwent DAo TAVR (2.0%, 95% CI \[0.9--4.7\]; *P* for heterogeneity = 0.023). The conversion rate was higher in the DAo TAVR group (2.8%, 95% CI \[2.1--3.6\]) than in the TAx TAVR group (0.9%, 95% CI \[0.6--1.6\]; *P* for heterogeneity \< 0.001). No significant differences in the other secondary outcomes were identified between the two groups ([Fig. 2](#fig-2){ref-type="fig"}).

Discussion
==========

TAx vs. DAo TAVR
----------------

TAx TAVR is the most commonly used percutaneous, nonfemoral approach that does not require general anesthesia or endotracheal intubation. TAx TAVR is also less invasive than DAo and TA TAVR because it does not require entering the chest cavity, thereby reducing lung complication risks, thus shortening the ventilator time and intensive care unit stay.

In DAo TAVR, the delivery system enters directly through the ascending aorta, which requires minimal manipulation of the peripheral vessels, thereby reducing the incidence of peripheral vascular complications. Furthermore, cardiac surgeons are more familiar with DAo TAVR than with TA TAVR; therefore, DAo TAVR use may improve bleeding control and prevent myocardial injury, which can result in impaired ventricular function and ventricular pseudoaneurysm.

Data from more than 5,000 patients were analyzed in our systematic review and meta-analysis, which is the largest sample that has been used to compare TAx and DAo TAVR outcomes. We found that TAx TAVR was associated with a lower 30-day mortality rate, compatible with the findings of previous studies ([@ref-13]; [@ref-15]). Moreover, TAx TAVR was associated with higher postoperative stroke and PPM implantation rates than was DAo TAVR. Studies have reported similar trends; however, statistical significance was not demonstrated in these studies, which may be due to insufficient sample sizes ([@ref-1]; [@ref-13]; [@ref-14]; [@ref-15]).

Stroke
------

Post-TAVR stroke occurrence remains a major concern and cause of increased morbidity and mortality. In the present meta-analysis, the stroke rate was higher in the TAx group than in the DAo group. The mechanism for the lower stroke rate after DAo TAVR is unclear. Transcranial Doppler studies have reported that cerebral embolism predominantly occurred during manipulation of the calcified aortic valve while prostheses were being positioned and implanted ([@ref-23]). The shorter distance and straight course between the device entry site (on the ascending aorta) and the aortic annulus of the DAo route may enable surgeons to implant the stented valve more accurately and rapidly with less aortic valve manipulation, resulting in fewer distal embolisms.

In contrast to DAo TAVR, TAx TAVR involves the advancement of the delivery catheter from the right or left subclavian artery to the ascending aorta, thus traversing the origins of the vertebral artery, carotid artery, aortic arch, and ascending aorta, which may induce atherosclerotic plaques and cerebral embolism. The flow of the vertebral artery or right carotid artery may be compromised during the procedure, particularly when the diameter of the innominate artery or left subclavian artery is only marginally wider than the delivery catheter. Moreover, TAx TAVR can cause vessel wall disruption along the innominate and subclavian arteries and the origins of the carotid and vertebral arteries, resulting in enhanced thrombogenicity, which may be linked to stroke ([@ref-4]).

PPM implantation
----------------

A study comparing TAx and DAo TAVR in four high-volume Italian centers concluded that the TAx route is an independent predictor for increased PPM implantation ([@ref-14])---compatible with our finding that PPM implantation rate was higher after TAx TAVR than after DAo TAVR. Implantation depth is known to be a predictor of PPM implantation after TAVR. DAo TAVR may provide better control over device placement than does TAVR with peripheral access, potentially resulting in better coaxial alignment and more accurate implant depth, thereby causing fewer conduction disturbances ([@ref-6]). Large-scale studies reported that TA TAVR was associated with a significantly lower rate of PVL than was TF TAVR ([@ref-26]; [@ref-46]). This finding suggests that more direct routes, such as DAo or TA, provide increased device placement control and thus lower PVL and PPM implantation rates. Furthermore, our meta-analysis indicated that TAx TAVR was associated with significantly higher valve malposition and numerically higher PVL compared with DAo TAVR (*P* = 0.113).

Study limitations
-----------------

First, all studies included in our analysis were observational, and thus, heterogeneity between the 2 groups was inevitable. However, the 2 groups cannot be accurately balanced without undertaking a randomized controlled trial. Second, to ensure the standardization of the definitions of stroke and other complications, we enrolled only the studies that used the VARC definitions; however, this limited the number of patients analyzed, thereby reducing the power of the meta-analysis. Third, the pace of reporting does not match the rapid advancement of TAVR technology; therefore, these results may not represent the real outcomes of the most recent devices.

Conclusions
===========

The present meta-analysis compared the outcomes of DAo and TAx TAVR. We determined that the 30-day mortality rate was higher in patients who underwent DAo TAVR, but the postoperative stroke and PPM implantation rates were higher in patients who underwent TAx TAVR. Our findings could help TAVR candidates with unsuitable femoral access optimize their selection of alternative access.
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